 This study will compare the effectiveness and safety of maintenance therapy with continuous bortezomib, lenalidomide, and dexamethasone VRD compared to maintenance therapy that alternates VRD with Elotuzumab, lenalidomide, and dexamethasone Elo RD every eight weeks. 